|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2003
|
|
gptkbp:ATCCode
|
A04AA05
|
|
gptkbp:brand
|
gptkb:Aloxi
Onicit
|
|
gptkbp:CASNumber
|
135729-62-3
|
|
gptkbp:chemicalClass
|
isoquinoline derivative
|
|
gptkbp:contraindication
|
hypersensitivity to palonosetron
|
|
gptkbp:developedBy
|
Helsinn Healthcare
|
|
gptkbp:eliminationHalfLife
|
~40 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
capsule
injection
|
|
gptkbp:hasMolecularFormula
|
C19H24N2O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
palonosetron
|
|
gptkbp:KEGGID
|
D08365
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:maximumDose
|
0.25 mg IV
0.5 mg oral
|
|
gptkbp:mechanismOfAction
|
5-HT3 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
62%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
119859
107010
DB00377
|
|
gptkbp:relatedTo
|
gptkb:ondansetron
gptkb:dolasetron
gptkb:granisetron
gptkb:tropisetron
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
constipation
dizziness
fatigue
headache
|
|
gptkbp:synonym
|
RS-25259
palonosetron hydrochloride
|
|
gptkbp:UNII
|
6L6XEX4372
|
|
gptkbp:usedFor
|
prevention of postoperative nausea and vomiting
prevention of chemotherapy-induced nausea and vomiting
|
|
gptkbp:bfsParent
|
gptkb:5-HT3_receptor
gptkb:serotonin_5-HT3_receptor
gptkb:Aloxi
|
|
gptkbp:bfsLayer
|
7
|